F10 and cancer: Several randomized trials have shown that oral factor Xa inhibitors are equivalent to subcutaneous LMWH in terms of safety and efficacy in preventing recurrent VTE or massive bleeding in cancer patients, making them an attractive choice for cancer‐related ESUS(Agnelli et al., 2020; Carrier et al., 2019; Khorana et al., 2019; Raskob et al., 2018).